G

ood day to you. This is Meghana of the Readout, filling in for Ed in this Wednesday edition of Pharmalittle. Here’s what’s happening in PharmaLand:

San Diego’s Neurocrine Biosciences won approval for its drug targeting tardive dyskinesia — a movement disorder seen in patients taking antipsychotic medication. This is the company’s first drug approval. Its stock leapt nearly 25 percent in premarket trading.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X